Conducting three or more pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures significantly enhances survival among patients with unresectable peritoneal surface malignancies. In a cohort of 346 patients undergoing 1200 treatments, approximately two-thirds completed at least three procedures. Disease progression was the primary reason for treatment cessation in over half of cases. The findings suggest that increasing the number of PIPAC treatments, particularly with systemic chemotherapy, correlates with better outcomes and warrants further prospective validation.
• Why it matters: Disease progression limits treatment options for advanced cancer patients.
Journal Article by Orgad R, Bakrin N (…) Kepenekian V et 5 al. in Ann Surg
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.